Please find attached Investor Presentation on Unaudited Financial Results for quarter ended June 30, 2026.

~ GALAXY Chemistry Creates Care August 13, 2026 National Stock Exchange of India Limited BSE Limited, Exchange Plaza, C-1, Block G, Listing Department, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, subBandra (East) Dalal Street, Mumbai – 400 051 Mumbai- 400001 Scrip Symbol: GALAXYSURF Scrip Code: 540935 Sub: Investor presentation on the Unaudited Financial Results for the quarter ended June 30, 2026. Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/ Madam, We are enclosing Investor Presentation on the Unaudited Financial Results for the quarter ended June 30, 2026. The information is also hosted in announcement section on the website of the Company at www.galaxysurfactants.com. We request you to take the same on record. Yours faithfully, For Galaxy Surfactants Limited Niranjan Ketkar Company Secretary encl: as above Galaxy Surfactants Ltd. Regd. Office: C-49/2, TTC Industrial Area, Pawne, Navi Mumbai 400 703 P +91-22-39135500 F +91-39135554 E galaxy@galaxysurfactants.com www.galaxysurfactants.com CIN No. L39877MH1986PLC039877 ~G A L A X Y Galaxy Surfactants Limited Result Presentation August’26 Chemistry Creates ::ire Safe Harbor ~ GALAXY Chemistry Creates Care This presentation and the accompanying slides (the “Presentation”), which have been prepared by Galaxy Surfactants Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. This Presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company. Chemistry Creates Care 2 Company at a Glance ~ GALAXY Chemistry Creates Care 7 Strategically Located Extensive R&D Capabilities 215+ Product Grades Facilities with Inhouse Project Execution Capabilities 100+ Members Performance Surfactants: 47+ R&D Centre Specialty Care Products: 168+ Pilot Plant 5 in India 1 in Egypt Product Application Centre 1 in US Presence across 2,000+ Employees Serving 1,500+ Clients 95+ countries across all our Facilities Chemistry Creates Care As on 30th June 2026 3 Q1FY27 Performance Highlights Management Commentary ~ GALAXY Chemistry Creates Care “I am pleased that the strategic foundations we have been building over the years have translated into tangible outcomes. Our ability to anticipate risks, manage volatility, make disciplined commercial decisions and leverage a diversified portfolio has enabled us to emerge stronger despite a challenging external environment. This performance is also a reflection of the exceptional efforts and collaboration demonstrated by our teams across business development, commercial excellence, procurement, global logistics, manufacturing and operations, who have ensured agility, continuity and flawless execution amidst significant external disruptions. While we remain watchful of evolving geopolitical developments and their impact on global supply chains, we are encouraged by the recovery in customer demand, the strong momentum in Specialty Care and the continued strength of our India business. Mr. K. Natarajan We remain confident in our ability to deliver sustainable long-term growth through disciplined Managing Director execution, customer centric approach and a continued focus on creating long-term value for all stakeholders.” Chemistry Creates Care 5 Key Developments ~ GALAXY Chemistry Creates Care Consolidated volume growth in the mid-single digits, with a balanced contribution from both Performance Surfactants and Specialty Care Strong earnings recovery, with EBITDA growing 87% YoY to ₹252 Cr and EBITDA/MT improving to ₹35,458/MT, driven by disciplined pricing, a favourable product mix within the Specialty Care segment, operational excellence, improved operating leverage and robust risk management, despite a volatile raw material environment India returned to double-digit volume growth after nearly two years, significantly outpacing market growth, driven by strong demand from Tier-1 customers and the return of reformulation-related volumes that had been impacted in earlier quarters AMET witnessed a low-single-digit YoY decline due to geopolitical disruptions in West Asia. Encouragingly, the region recorded high-teen sequential growth, indicating a steady improvement in market conditions and a recovery in demand ROW delivered mid-single-digit growth, led by APAC and improving momentum in the Americas following the revision of US tariffs Raw material markets remained volatile, with elevated fatty alcohol prices and higher petrochemical feedstock costs following the increase in crude oil prices Chemistry Creates Care 6 Segment Performance Highlights: Q1FY27 ~ GALAXY Chemistry Creates Care Performance Surfactants Revenue Specialty Care Revenue Total Revenue ₹ 1,178.7 cr ₹ 603.2 cr ₹ 1,781.9 cr Volume Summary Category Overall Mid Performance Surfactant Mid Single Digit Growth Single Digit Specialty Care Mid Single Digit Growth Volume Growth Regions on YoY India Low Double Digit Growth AMET Low Single Digit Decline ROW Mid Single Digit Growth Chemistry Creates Care 7 Consolidated Performance: Q1FY27 ~ GALAXY Chemistry Creates Care Rs in cr Total Revenue EBITDA PAT +38% +87% +109% 1,785 253 166 1,315 1,289 122 79 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Q1FY26 Q4FY26 Q1FY27 Chemistry Creates Care 8 Revenue Performance: Q1FY27 ~ GALAXY Chemistry Creates Care Category Customer Region wise Revenue 44% 43% 65% 66% 9% 22% 21% 35% 34% 42% 39% 34% 36% Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Performance Surfactants MNC Customer Local & Niche Player India AMET ROW Specialty Care Products Regional Players Chemistry Creates Care 9 Consolidated Profit & Loss Statement ~ GALAXY Chemistry Creates Care Particulars (Rs. In Crores) Q1FY27 Q1FY26 Y-o-Y Q4FY26 Q-o-Q FY26 Net Revenue from Operations 1,781.9 1,277.9 39.4% 1,314.7 35.5% 5,248.3 Other Income 3.3 11.2 0.3 22.1 Total Revenue 1,785.2 1,289.2 38.5% 1,315.0 35.8% 5,270.4 Cost of Material Consumed 1,260.3 942.8 975.1 3,917.7 Employee's Benefits Expense 100.1 83.5 83.9 328.1 Fatty Alcohol prices in Other Expenses 172.2 127.8 134.0 527.3 this quarter increased EBITDA 252.5 [Showing first 8,000 characters — download PDF for full document]